Yakult Honsha, Terumo to Co-develop Liposomal Formulation of Irinotecan.Tokyo, Japan, May 19, 2006 - (JCN JCN Japan Corporate News JCN Journal of Cognitive Neuroscience JCN Journal of Cardiovascular Nursing JCN Journal of Christian Nursing JCN Job Control Number JCN Journal of Child Neurology JCN joint communications network (US DoD) ) - Yakult Honsha announced on May 18 that it will develop a liposomal formulation of irinotecan, a kind of anticancer agent, with Terumo. A development code for the agent is IHL-305. Encapsulating irinotecan into a liposome liposome (lī`pəsōm', lĭp`ə–), microscopic, fluid-filled pouch whose walls are made of layers of phospholipids identical to the phospholipids that make up cell membranes. developed by Terumo, the new agent will be able to sustain its effectiveness and improve its concentration in cancer tissues while reducing side effects Side effects Effects of a proposed project on other parts of the firm. . As an initial step, the two companies will begin a phase 1 clinical trial phase 1 clinical trial Phase 1 study. See Phase study. in the US by the end of May. Copyright [c] 2006 Japan Corporate News Network. All rights reserved. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion